TY - JOUR
T1 - Outcomes of elderly patients with stage IIIB-IV non-small cell lung cancer admitted to the intensive care unit
AU - Bonomi, Marcelo R.
AU - Smith, Cardinale B.
AU - Mhango, Grace
AU - Wisnivesky, Juan P.
N1 - Funding Information:
This work was supported in part by a Research Supplement to Promote Diversity in Health-Related Research Program Award Number [R01CA131348] from the National Cancer Institute.
Funding Information:
Dr. Wisnivesky is a member of the research board of EHE International, has received lecture fees from Novartis Pharmaceutical, consulting honorarium from UBC, and a research grant from GlaxoSmithKline. The remaining authors have no relevant relationships to disclose.
PY - 2012/9
Y1 - 2012/9
N2 - Background: Although the prognosis of elderly patients with stage IIIB and IV non-small cell lung cancer (NSCLC) is poor, it remains a common cause of cancer related admissions to the intensive care unit (ICU). The objective was to evaluate short and long-term outcomes of a population-based sample of elderly patients with advanced NSCLC who require ICU care. Methods: Using combined data from the Surveillance, Epidemiology and End Results registry and Medicare files, we identified 1134 patients >65 years of age with stage IIIB and IV NSCLC admitted to an ICU with a diagnosis of respiratory, cardiac, or neurologic complications, renal failure, or sepsis. We assessed rates and predictors of death during hospitalization. The Kaplan-Meier method was used to estimate mortality rates at 90 days and 1 year post hospital discharge. Results: In-hospital mortality was 33% (95% CI: 30-36%). The 90-day and 1-year mortality rate was 71% and 90%, respectively. Patients with an admitting diagnosis of sepsis had the highest rate of in-hospital mortality (59%). Of those who were alive at discharge, 52% were transferred to a skilled nursing facility, 6% to hospice, and 42% returned home. Conclusion: We found that one-third of elderly patients with advanced NSCLC admitted to the ICU do not survive hospitalization. Among survivors, most patients required continued institutionalization with a very low likelihood of surviving >1 year from discharge. This data should help patients, families, and health care providers of elderly patients with advanced NSCLC make decisions regarding ICU utilization.
AB - Background: Although the prognosis of elderly patients with stage IIIB and IV non-small cell lung cancer (NSCLC) is poor, it remains a common cause of cancer related admissions to the intensive care unit (ICU). The objective was to evaluate short and long-term outcomes of a population-based sample of elderly patients with advanced NSCLC who require ICU care. Methods: Using combined data from the Surveillance, Epidemiology and End Results registry and Medicare files, we identified 1134 patients >65 years of age with stage IIIB and IV NSCLC admitted to an ICU with a diagnosis of respiratory, cardiac, or neurologic complications, renal failure, or sepsis. We assessed rates and predictors of death during hospitalization. The Kaplan-Meier method was used to estimate mortality rates at 90 days and 1 year post hospital discharge. Results: In-hospital mortality was 33% (95% CI: 30-36%). The 90-day and 1-year mortality rate was 71% and 90%, respectively. Patients with an admitting diagnosis of sepsis had the highest rate of in-hospital mortality (59%). Of those who were alive at discharge, 52% were transferred to a skilled nursing facility, 6% to hospice, and 42% returned home. Conclusion: We found that one-third of elderly patients with advanced NSCLC admitted to the ICU do not survive hospitalization. Among survivors, most patients required continued institutionalization with a very low likelihood of surviving >1 year from discharge. This data should help patients, families, and health care providers of elderly patients with advanced NSCLC make decisions regarding ICU utilization.
KW - Elderly
KW - Intensive care unit
KW - Lung cancer
KW - Mortality
UR - https://www.scopus.com/pages/publications/84865159165
U2 - 10.1016/j.lungcan.2012.05.103
DO - 10.1016/j.lungcan.2012.05.103
M3 - Article
C2 - 22709929
AN - SCOPUS:84865159165
SN - 0169-5002
VL - 77
SP - 600
EP - 604
JO - Lung Cancer
JF - Lung Cancer
IS - 3
ER -